Business
Marina Biotech Appoints Amit Shah as Chief Financial Officer
Marina Biotech Appoints Amit Shah as Chief Financial Officer.
About this update from Adhera Therapeutics Inc.
[{"type":"text","content":"\n\n City of Industry, CA, Oct. 05, 2017 (GLOBE NEWSWIRE) -- Marina Biotech, Inc. (OTCQB: MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for hypertension, arthritis, pain and oncology, announced today that Amit Shah will join the company in the newly created role of Chief Financial Officer, effective immediately.\n Prior to joining Marina, Mr. Shah served as Senior Director of Finance – ERP, at Young’s Market Company. Prior to Young’s, he was the Vice President of Finance & Accounting, and Acting Chief Financial Officer, of Insightra Medical Inc.  Mr. Shah also previously served as VP Finance and Acting Chief Financial Officer at IgDraSol Inc., as Corporate Controller & Director of Finance at ISTA Pharmaceuticals, as Corporate Controller at Spectrum Pharmaceuticals, and Controller/Senior Manager Internal Audits at Caraco Pharmaceuticals Laboratories.  Mr. Shah received a Bachelor’s of Commerce degree from the University of Mumbai, and is an Associate Chartered Accountant from The Institute of Chartered Accountants of India. Mr. Shah is also an inactive CPA from Colorado, USA. “We are thrilled to have Amit join the Marina Biotech team to establish a strong finance and accounting organization for Marina Biotech. Amit brings with him over 15 years of strong financial, accounting and auditing experience to Marina,” stated Joseph Ramelli, CEO of Marina Biotech. “Our recent acquisition of the FDA approved therapy Prestalia represents a large and attractive market opportunity for Marina, which made finding the right Chief Financial Officer essential. I am confident that Amit is that person.” Mr. Shah stated, “The opportunity to work with the leadership at Marina on a new vision for building a strong finance and accounting organization for Marina, as well as growing the company through sales of Prestalia is exciting.  I am equally excited to be contributing to the transition of Marina into a strong and growing commercial organization. There are several promising therapies in our clinical pipeline that, if they are approved by the FDA, we could bring to market using the sales and marketing platforms developed for Prestalia.” About Prestalia® Prestalia contains perindopril arginine, an ACE...